Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-022-2 | CAS number: 16949-65-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Reliable information on acute oral toxicity indicates that the substance shall be classified according to in force regulations.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- not specified
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: mean 177g (male) 157g (female)
- Fasting period before study: 15h-20h
- Diet (e.g. ad libitum): Herilan MRH-Haltung - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- distilled water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 50%, 10%, 6.81%, 4.64%, 3.16%, 2.15%
- Amount of vehicle (if gavage) (ml/kg): 10
MAXIMUM DOSE VOLUME APPLIED: 5000 mg/kg - Doses:
- 6 dose groups:
Dosis: 5000 mg/kg, 1000 mg/kg, 681 mg/kg, 464 mg/kg, 316 mg/kg, 215 mg/kg - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: 2-4 D, 7 D and 13 D
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs (dyspnoe, rattle, apathy, anomalous situation, stagger, atony, pain reflex, cornea reflex, anesthesia, tremble, twitch, clonic convulsions, shaggy fur, diarrhea, cyanosis, exsiccosis, chromodacryorrhea, general worse), body weight - Statistics:
- Model of the dose-effect relationship: F(P) = A + B·LN(D)
Explanation: D=Dosis; P=Relative frequency of the dead animals after exposure to D; F=Inverse function of the cumulative normal distribution stander; LN=Natural logarithm; A,B= model parameters
Result: A=-26.26 scattering A=7.89; B=4.63 scattering B=1.39 - Preliminary study:
- NA
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 291 mg/kg bw
- Based on:
- dissolved
- 95% CL:
- > 246 - < 342
- Mortality:
- Dosis mg/kg Mortality after 14D %
215 10
316 60
464 100
6 81 100
1000 100
5000 100 - Clinical signs:
- other: symptoms (dosis with symptoms mg/kg) dyspnoe (5000, 1000, 681, 464, 316) rattle (1000) apathy (5000, 1000, 681, 464, 316) anomalous situation (5000, 1000, 681, 464) stagger (1000, 681, 464, 316) atony (5000, 681) pain reflex (681) cornea reflex (681) anes
- Gross pathology:
- Animals that died: heart: right acute dilatation, acute hyperaemia; stomach: glandular stomach diffusely reddened, partly large-scale bloody ulcers, intestinal: atonic, reddened mucous membrane inflammation
- Other findings:
- NA
- Interpretation of results:
- toxic
- Remarks:
- Migrated information Acute Tox. 3 Criteria used for interpretation of results: EU
- Conclusions:
- The results showed a LD50 after 14 days of 291 mg/kg.
- Executive summary:
In an in vivo test, the acute oral toxicity effects in rats of Magnesium Hexafluorosilicate Hexahydrated
were studied.The product was administered by gavage once to the animals. The investigations included the mortality in 14 days, poisoning symptoms and section of acute died and died after the test period with carbon dioxide. The animals were 30 male and 30 female Sprague Dawley Wiga Rats. The substance was administrated as a solution with distillated water via oral with a fasting period of 15-20 hours for application. The rats were divided in six test groups (5 male/ 5 female) with different dosis (5000 mg/kg, 1000 mg/kg, 681 mg/kg, 464 mg/kg, 316 mg/kg, 215 mg/kg). The results showed a LD50 after 14 days of 291 mg/kg with a slope factor of 1,24.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 291 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: WIGA
- Weight at study initiation: 185 +/- 15 g
- Diet: Herilan MRH
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2 ºC
- Humidity (%): 55 +/- 5 %
- Photoperiod (hrs dark / hrs light): 12 h dark/12 h light - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose/head only
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION/ TEST ATMOSPHERE
- Exposure apparatus: cascaded impinger and downstream frits bottle
- Method of holding animals in test chamber: The animals sit in tubes with their snouts in the inhalation space
- Place of sampling: in the immediate vicinity of the animal noses
- Brief description of analytical method used: Titrimetric determination of magnesium - Analytical verification of test atmosphere concentrations:
- not specified
- Duration of exposure:
- ca. 4 h
- Concentrations:
- Concentrations (mg/l) (5 dosis-groups):
nominal: 9.92, 7.85, 7.44, 4.81, 1.18
analytical: 6.06, 5.86, 4.16, 3.15, 1.07 - No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: 7 days and 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, pathology - Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- ca. 3.6 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- ca. 14.4 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 1 h
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- ca. 3.9 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Sex:
- female
- Dose descriptor:
- LC50
- Effect level:
- ca. 3.4 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- ca. 15.6 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 1 h
- Sex:
- female
- Dose descriptor:
- LC50
- Effect level:
- ca. 13.6 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 1 h
- Mortality:
- Dosis-group 1 (analytical concentration 6,06 mg/l) mortality (dead/exposed): 9/10 (male), 10/10 (female)
Dosis-group 2 (analytical concentration 5,86 mg/l) mortality (dead/exposed): 5/10 (male), 3/10 (female)
Dosis-group 3 (analytical concentration 4,16 mg/l) mortality (dead/exposed): 8/10 (male), 9/10 (female)
Dosis-group 4 (analytical concentration 3,15 mg/l) mortality (dead/exposed): 3/10 (male), 5/10 (female)
Dosis-group 5 (analytical concentration 1m07 mg/l) mortality (dead/exposed): 0/10 (male), 0/10 (female) - Clinical signs:
- other: Dosis-group 1-4: watery or red eyes, and nasal discharge, dyspnoea, tremor (group 1), staggering gait, crouch, apathy (group 1, 3); shaggy and glued fur. Dosis-group 5: watery eye discharge, reddish nasal discharge, subsequently reddish encrusted noses
- Body weight:
- Group 1
Before trial: 185 g (male, number of animals: 10), 181 g (female, number of animals: 10)
After 7 days: 117 g (male, number of animals: 1), -
After 14 days: 146 g (male, number of animals: 1), -
Group 2
Before trial: 186 g (male, number of animals: 10), 188 g (female, number of animals: 10)
After 7 days: 163 g (male, number of animals: 5), 195 g (male, number of animals: 7)
After 14 days: 215 g (male, number of animals: 5), 212 g (male, number of animals: 7)
Group 3
Before trial: 174 g (male, number of animals: 10), 185 g (female, number of animals: 10)
After 7 days: 173 g (male, number of animals: 2), 189 g (male, number of animals: 1)
After 14 days: 243 g (male, number of animals: 2), 224 g (male, number of animals: 1)
Group 4
Before trial: 191 g (male, number of animals: 10), 188 g (female, number of animals: 10)
After 7 days: 209 g (male, number of animals: 7), 190 g (male, number of animals: 5)
After 14 days: 263 g (male, number of animals: 7), 208 g (male, number of animals: 5)
Group 5
Before trial: 187 g (male, number of animals: 10), 183 g (female, number of animals: 10)
After 7 days: 234 g (male, number of animals: 10), 204 g (male, number of animals: 10)
After 14 days: 292 g (male, number of animals: 10), 219 g (male, number of animals: 10)
Control Group
Before trial: 183 g (male, number of animals: 10), 182 g (female, number of animals: 10)
After 7 days: 231 g (male, number of animals: 10), 199 g (male, number of animals: 10)
After 14 days: 274 g (male, number of animals: 10), 214 g (male, number of animals: 10) - Gross pathology:
- Heart: acute dilation or acute hyperaemia; lung: multiple patchy blood and wealth edemous, multiple acute flatulence center of learning degree.
- Other findings:
- Organ o. B.
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information harmful if inhaled Criteria used for interpretation of results: EU
- Conclusions:
- harmful if inhaled
- Executive summary:
In an in vivo test, the acute inhalation effects in rats of Magnesium Hexafluorosilicate Hexahydrated were studied according to a dynamic head-nose inhalation method with an analytical and nominal determination of exposure concentration (aerosol exposition). The animals were Sprague-Dawley rats divided in five dose groups (10 male / 10 female for each dose), the body weight of the rats was 185±15 g.
The results showed a LC50 (4 hours) for male and female of 3,6 mg/L of air and a LC50 (1 hour) for male and female of 14,4 mg/L of air.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 3 900 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In an in vivo test, the acute oral toxicity effects in rats of Magnesium Hexafluorosilicate hexahydrated was studied. The study performed in 1980 has shown a LD50 after 14 days of 291 mg/kg.
An in vivo test of acute inhalation toxicity in rat of magnesium hexafluorosilicate hexahydrated gave a LC50 of 3.9 mg/l.
Justification for classification or non-classification
This substance is classified according to the CLP Regulation (EC) 1272/2008 in Oral Acute Toxicity Category 3.
However, according to an in vivo study for acute inhalation toxicity, magnesium hexafluorosilicate hexahydrated should also be classified as Inhalation Acute Toxicity Category 4.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.